The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InMedicus Pharma (NASDAQ: MDCX) has announced successful results from its Phase 2 clinical trial evaluating a non-invasive treatment for basal cell carcinoma. The study utilized a doxorubicin microneedle array (D-MNA) delivery system, representing a significant advancement in non-surgical chemotherapy. According to the report, the highest-dose group achieved a 73% clinical clearance rate of cancerous lesions. The randomized, placebo-controlled trial involved 90 patients suffering from nodular basal cell carcinoma to evaluate the efficacy of the treatment. These positive results mark a critical milestone for the biotech firm, potentially paving the way for future commercialization. Investors are closely monitoring the company as it moves closer to providing a viable alternative to traditional invasive procedures.